When an industry enjoys significant growth, individual stock valuations often rise with the tide. This firm’s inability to grow profits amidst record industry revenues raises a red flag. Add in significant competition, lagging margins, and an overvalued stock price, and it’s hard to justify any bull case. Nevertheless, this stock is up 48% over the past year. For these reasons and more,....More>>>
The Federal Reserve raised its target of the federal-funds rate, the interest rate banks charge each other for overnight loans, by a quarter point to a range of 0.75% to 1%, and thats great news for Warren Buffetts Berkshire Hathaway (BRK.B) and its shareholders. As a bondholder, owner of insurance companies and an investor in big banks, Berkshire profits from rising interest rates in a number....More>>>
Unsatisfied with the status quo, the intrepid business leaders on Forbes’ second annual Global Game Changers list are transforming their industries and changing the lives of billions of people around the globe.
These trailblazers are re-imagining countless facets of our lives, from the way we think about our health (23andMe’s Anne Wojcicki) to the way we tackle....More>>>
Berkshire Hathaway CEO Warren Buffett (Trades, Portfolio) extolled many of his portfolio holdings for repurchasing their shares, “some quite aggressively,” in his 2016 annual letter. Buffett, who is price-conscious and won’t repurchase his own companies’ shares at more than 1.2 times book value, a statement he last made good on in 2012, approved of his investees’....More>>>
According to Collectors Universe's (NASDAQ:CLCT) companys description, We provide authentication and grading services to dealers and collectors of coins, trading cards, event tickets, autographs and historical and sports memorabilia (collectibles). We believe that our authent
On Friday, small cap cancer stock Mirati Therapeutics (NASDAQ: MRTX) surged 135.79% inheavy trading volume after announcing positive lung cancer treatment trial results. Mirati Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products in
Shares of Ignyta (NASDAQ:RXDX) have more than doubled over the past year, with news in May that the company received the coveted Breakthrough Therapy Designation for entrectinib providing momentum for the next leg up.
To begin this article, let's take a trip back to July 27th. AstraZeneca (NYSE:AZN) investors received the worst possible news with the news headline "AstraZeneca lung cancer immunotherapy trial failure sends shares plunging" effectively summing everything up. Shares absolutely
Just as the body's normal stem cells renew and sustain organs and tissue, cancer stem cells do the same for tumors. Large cap drugmaker AbbVie (NYSE:ABBV) is taking the lead in developing drugs to go after cancer stem cells, and long-term investors could enjoy the payoff.